Córdoba, May 11st 2015. For two consecutive years, VivaCell-sponsored research has been awarded in the VI Meeting of Young Researches organized by Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC). The awarded young researcher Carmen del Rio presented the promising effect of VCE-003.2 on neuronal stem cell prosurvival and on alleviation of symtomatology in murine models of Huntington Disease. VCE-003.2 is a novel non-electrophilic derivative of VCE-003 with neuroprotective activity and PPARγ agonist. VCE-003.2 belongs to a second generation of VCE-003 a cannabigerol quinone analogs protected by patent owned by VivaCell. The awarded research has been performed in collaboration by Dr. Galve-Roperh from Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) at Universidad Complutense of Madrid, and by Dr. Muñoz-Blanco at IMIBIC.